Daniela Mara de Oliveira

Daniela Mara de Oliveira

Auto-generated profile, based on publicly available information

Daniela Mara de Oliveira

Department of Genetics and Morphology, University of Brasília, Brasília, Brazil

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2016 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
DMDaniela Abreu De Moraes
Daniela Abreu De Moraes
TSTatiana T. Sibov
Tatiana T. Sibov
LPLorena F. Pavon
Lorena F. Pavon
PAPaula Q. Alvim
Paula Q. Alvim
RBRaphael Bonadio
Raphael Bonadio
DODaniela M. Oliveira
Daniela M. Oliveira
Background: Mesenchymal stromal cells (MSCs) are multipotent progenitor cells used in several cell therapies. MSCs are characterized by the expression of CD73, CD90, and CD105 cell markers, and the absence of CD34, CD45, CD11a, CD19, and HLA-DR cell markers. CD90 is a glycoprotein present in the MSC membranes and also in adult cells and cancer stem cells. The role of CD90 in MSCs remains unknown. Here, we sought to analyse the role that CD90 plays in the characteristic properties of in vitro expanded human MSCs. Methods: We investigated the function of CD90 with regard to morphology, proliferation rate, suppression of T-cell proliferation, and osteogenic/adipogenic differentiation of MSCs by reducing the expression of this marker using CD90-target small hairpin RNA lentiviral vectors. Results: The present study shows that a reduction in CD90 expression enhances the osteogenic and adipogenic differentiation of MSCs in vitro and, unexpectedly, causes a decrease in CD44 and CD166 expression. Conclusion: Our study suggests that CD90 controls the differentiation of MSCs by acting as an obstacle in the pathway of differentiation commitment. This may be overcome in the presence of the correct differentiation stimuli, supporting the idea that CD90 level manipulation may lead to more efficient differentiation rates in vitro.

12 February 2012 in Cytotechnology
Verified
Journal Article
Closed access
PDF file
TSTatiana Taís Sibov
Tatiana Taís Sibov
PSPatricia Severino
Patricia Severino
LMLuciana Marti
Luciana Marti
LPL. F. Pavon
L. F. Pavon
DOD. M. Oliveira
D. M. Oliveira
CMC. A. Moreira-Filho
C. A. Moreira-Filho

9 November 2018 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
LPLorena Favaro Pavon
Lorena Favaro Pavon
TSTatiana Tais Sibov
Tatiana Tais Sibov
ASAndrea Vieira de Souza
Andrea Vieira de Souza
ECEdgar Ferreira da Cruz
Edgar Ferreira da Cruz
SMSuzana M. F. Malheiros
Suzana M. F. Malheiros
SCSérgio Cavalheiro
Sérgio Cavalheiro
Previous studies have demonstrated remarkable tropism of mesenchymal stem cells (MSCs) toward malignant gliomas, making these cells a potential vehicle for delivery of therapeutic agents to disseminated glioblastoma (GBM) cells. However, the potential contribution of MSCs to tumor progression is a matter of concern. It has been suggested that CD133+ GBM stem cells secrete a variety of chemokines, including monocytes chemoattractant protein-1 (MCP-1/CCL2) and stromal cell-derived factor-1(SDF-1/CXCL12), which could act in this tropism. However, the role in the modulation of this tropism of the subpopulation of CD133+ cells, which initiate GBM and the mechanisms underlying the tropism of MSCs to CD133+ GBM cells and their effects on tumor development, remains poorly defined. We found that isolated and cultured MSCs (human umbilical cord blood MSCs) express CCR2 and CXCR4, the respective receptors for MCP-1/CCL2 and SDF-1/CXCL12, and demonstrated, in vitro, that MCP-1/CCL2 and SDF-1/CXC12, secreted by CD133+ GBM cells from primary cell cultures, induce the migration of MSCs. In addition, we confirmed that after in vivo GBM tumor establishment, by stereotaxic implantation of the CD133+ GBM cells labeled with Qdots (705 nm), MSCs labeled with multimodal iron oxide nanoparticles (MION) conjugated to rhodamine-B (Rh-B) (MION-Rh), infused by caudal vein, were able to cross the blood-brain barrier of the animal and migrate to the tumor region. Evaluation GBM tumors histology showed that groups that received MSC demonstrated tumor development, glial invasiveness, and detection of a high number of cycling cells. Therefore, in this study, we validated the chemotactic effect of MCP-1/CCL2 and SDF-1/CXCL12 in mediating the migration of MSCs toward CD133+ GBM cells. However, we observed that, after infiltrating the tumor, MSCs promote tumor growth in vivo probably by release of exosomes. Thus, the use of these cells as a therapeutic carrier strategy to target GBM cells must be approached with caution.

3 July 2012 in International Endodontic Journal
Verified
Journal Article
Closed access
PDF file
LPL. O. Pereira
L. O. Pereira
MRMarciano Régis Rubini
Marciano Régis Rubini
JSJ. R. Silva
J. R. Silva
DOD. M. Oliveira
D. M. Oliveira
ISIZABEL CRISTINA RODRIGUES DA SILVA
IZABEL CRISTINA RODRIGUES DA SILVA
RAR. B. Azevedo
R. B. Azevedo

18 July 2016 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
LSLuisa H. A. Silva
Luisa H. A. Silva
JSJaqueline R Da Silva
Jaqueline R Da Silva
GFGuilherme A. Ferreira
Guilherme A. Ferreira
RSRenata C. Silva
Renata C. Silva
ELEmilia C. D. Lima
Emilia C. D. Lima
DODaniela M. Oliveira
Daniela M. Oliveira
Nanoparticles’ unique features have been highly explored in cellular therapies. However, nanoparticles can be cytotoxic. The cytotoxicity can be overcome by coating the nanoparticles with an appropriated surface modification. Nanoparticle coating influences biocompatibility between nanoparticles and cells and may affect some cell properties. Here, we evaluated the biocompatibility of gold and maghemite nanoparticles functionalized with 2,3-dimercaptosuccinic acid (DMSA), Au-DMSA and γ-Fe2O3-DMSA respectively, with human mesenchymal stem cells. Also, we tested these nanoparticles as tracers for mesenchymal stem cells in vivo tracking by computed tomography and as agents for mesenchymal stem cells magnetic targeting. Significant cell death was not observed in MTT, Trypan Blue and light microscopy analyses. However, ultra-structural alterations as swollen and degenerated mitochondria, high amounts of myelin figures and structures similar to apoptotic bodies were detected in some mesenchymal stem cells. Au-DMSA and γ-Fe2O3-DMSA labeling did not affect mesenchymal stem cells adipogenesis and osteogenesis differentiation, proliferation rates or lymphocyte suppression capability. The uptake measurements indicated that both inorganic nanoparticles were well uptaken by mesenchymal stem cells. However, Au-DMSA could not be detected in microtomograph after being incorporated by mesenchymal stem cells. γ-Fe2O3-DMSA labeled cells were magnetically responsive in vitro and after infused in vivo in an experimental model of lung silicosis. In terms of biocompatibility, the use of γ-Fe2O3-DMSA and Au-DMSA as tracers for mesenchymal stem cells was assured. However, Au-DMSA shown to be not suitable for visualization and tracking of these cells in vivo by standard computed microtomography. Otherwise, γ-Fe2O3-DMSA shows to be a promising agent for mesenchymal stem cells magnetic targeting.

2 January 2002 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
GBGurminder S. Bassi
Gurminder S. Bassi
DODaniela M. de Oliveira
Daniela M. de Oliveira
MWMalcolm F. White
Malcolm F. White
KWKevin M. Weeks
Kevin M. Weeks
Detectable splicing by the Saccharomyces cerevisiae mitochondrial bI3 group I intron RNA in vitro is shown to require both an intron-encoded protein, the bI3 maturase, and the nuclear-encoded protein, Mrs1. Both proteins bind independently to the bI3 RNA. The bI3 maturase binds as a monomer, whereas Mrs1 is a dimer in solution that assembles as two dimers, cooperatively, on the RNA. The active six-subunit complex has a molecular mass of 420 kDa, splices with a k cat of 0.3 min −1 , and binds the guanosine nucleophile with an affinity comparable to other group I introns. The functional bI3 maturase domain is translated from within the RNA that encodes the intron, has evolved a high-affinity RNA-binding activity, and is a member of the LAGLIDADG family of DNA endonucleases, but appears to have lost DNA cleavage activity. Mrs1 is a divergent member of the RNase H fold superfamily of dimeric DNA junction-resolving enzymes that also appears to have lost its nuclease activity and now functions as a tetramer in RNA binding. Thus, the bI3 ribonucleoprotein is the product of a process in which a once-catalytically active RNA now obligatorily requires two facilitating protein cofactors, both of which are compromised in their original functions.